Education
About Us
Working with TipRanks
Follow Us
ADC Therapeutics Ltd (ADCT)
NYSE:ADCT
Total Valuation
ADC Therapeutics has a market cap or net worth of $491.79M. The enterprise value is $768.48M.
Market Cap$491.79M
Enterprise Value$768.48M
Share Statistics
ADC Therapeutics has 123,877,110 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding123,877,110
Owned by Insiders34.40%
Owned by Institutions30.39%
Financial Efficiency
ADC Therapeutics’s return on equity (ROE) is 0.78 and return on invested capital (ROIC) is -53.85%.
Return on Equity (ROE)0.78
Return on Assets (ROA)-0.49
Return on Invested Capital (ROIC)-53.85%
Return on Capital Employed (ROCE)-0.54
Revenue Per Employee269.34K
Profits Per Employee-600.17K
Employee Count263
Asset Turnover0.22
Inventory Turnover0.32
Valuation Ratios
The current PE Ratio of ADC Therapeutics is ―. ADC Therapeutics’s PEG ratio is 0.03.
PE Ratio―
PS Ratio2.73
PB Ratio-0.95
Price to Fair Value-0.95
Price to FCF-1.55
Price to Operating Cash Flow-4.25
PEG Ratio0.03
Income Statement
In the last 12 months, ADC Therapeutics had revenue of 70.84M and earned -157.85M in profits. Earnings per share was -1.62.
Revenue70.84M
Gross Profit64.89M
Operating Income-130.65M
Pretax Income-157.68M
Net Income-157.85M
EBITDA-102.65M
Earnings Per Share (EPS)-1.62
Cash Flow
In the last 12 months, operating cash flow was -131.90M and capital expenditures -354.00K, giving a free cash flow of -132.26M billion.
Operating Cash Flow-131.90M
Free Cash Flow-132.26M
Free Cash Flow per Share-1.07
Dividends & Yields
ADC Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.49
52-Week Price Change94.17%
50-Day Moving Average3.98
200-Day Moving Average2.72
Relative Strength Index (RSI)47.03
Average Volume (3m)858.18K
Important Dates
ADC Therapeutics upcoming earnings date is Mar 12, 2026, Before Open (Confirmed).
Last Earnings DateNov 10, 2025
Next Earnings DateMar 12, 2026
Ex-Dividend Date―
Financial Position
ADC Therapeutics as a current ratio of 3.82, with Debt / Equity ratio of -59.00%
Current Ratio3.82
Quick Ratio3.59
Debt to Market Cap0.59
Net Debt to EBITDA1.23
Interest Coverage Ratio-2.60
Taxes
In the past 12 months, ADC Therapeutics has paid 166.00K in taxes.
Income Tax166.00K
Effective Tax Rate>-0.01
Enterprise Valuation
ADC Therapeutics EV to EBITDA ratio is -0.63, with an EV/FCF ratio of -0.53.
EV to Sales0.92
EV to EBITDA-0.63
EV to Free Cash Flow-0.53
EV to Operating Cash Flow-0.53
Balance Sheet
ADC Therapeutics has $234.74M in cash and marketable securities with $117.27M in debt, giving a net cash position of $117.47M billion.
Cash & Marketable Securities$234.74M
Total Debt$117.27M
Net Cash$117.47M
Net Cash Per Share$0.95
Tangible Book Value Per Share-$2.09
Margins
Gross margin is 92.66%, with operating margin of -184.44%, and net profit margin of -222.83%.
Gross Margin92.66%
Operating Margin-184.44%
Pretax Margin-220.42%
Net Profit Margin-222.83%
EBITDA Margin-146.41%
EBIT Margin-151.03%
Analyst Forecast
The average price target for ADC Therapeutics is $7.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$7.33
Price Target Upside83.25% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast6.35%
EPS Growth Forecast39.57%